Level of SARS-CoV-2 exposure post the CoronaVac vaccination in health workers at Dr. Saiful Anwar General Hospital, Malang
Main Article Content
Keywords
COVID-19, SARS-CoV-2 exposure, CoronaVac
Abstract
Introduction. COVID-19 is considered a new emerging infection due to SARS-CoV-2. CoronaVac refers to an inactivated SARS-CoV-2 vaccine obtaining EUL (Emergency use listing) from BPOM RI and WHO. This vaccine was previously reported to exhibit good efficacy in generating protective antibodies against SARS-CoV-2. Nevertheless, health workers in Indonesia might pose a high risk of COVID-19 exposure, leading to mortality. This study aims to identify the level of SARS-CoV-2 exposure to the CoronaVac vaccination in health workers at Dr. Saiful Anwar General Hospital, Malang.
Methods. This study implemented analytical observational research with a prospective cohort approach on health workers at Dr. Saiful Anwar General Hospital, Malang, who received the 2nd dose of vaccination dose with a 14-day interval. All study subjects were observed for 6 months by examining the level of exposure to SARS-CoV-2 obtained from the results of nasopharyngeal and oropharyngeal swab examinations of SARS-CoV-2 RT PCR examination. Categorical data were tested by using Chi-square or Fisher exact.
Results. From 184 samples, the SARS-CoV-2 exposure indicated several outcomes: positive 57 (31 %) and negative 127 (69%). Severity degrees of COVID-19 disease were asymptomatic 17 (29.8%), mild 37 (64.9), moderate 3 (5.3%), severe 0 (0%), and there were no mortality cases. The time (duration) of exposure to SARS-CoV-2 post-CoronaVac vaccination indicated that the highest number of participants with positive RT-PCR swab results post-vaccination was in the fifth month of the CoronaVac vaccination with 41 people. Clinical symptoms of SARS-CoV-2 exposure experienced by participants post the CoronaVac vaccination included pneumonia (3 people), cough and cold (27 people), fever (22 people), myalgia (17 people), and sore throat (11 people). There was no significant relationship p value > 0.05 between gender, age, comorbidities, and Ct value on SARS-CoV-2 exposure post CoronaVac vaccination in health workers at Dr. Saiful Anwar General Hospital, Malang.
Conclusion. There was SARS-CoV-2 exposure of 31% post the CoronaVac vaccination in health workers at Dr. Saiful Anwar General Hospital, Malang.
References
2. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia. 2020;7(1):45.
3. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069–76.
4. WHO. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine. SAGE Working Group on COVID-19 vaccines. 2021. p. 1–32.
5. BPOM. FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CORONAVAC. 2021 Aug.
6. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92.
7. WHO. Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables. 2021. p. 1–50.
8. Can G, Acar HC, Aydin SN, Balkan II, Karaali R, Budak B, et al. Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers. Vaccine. 2022;40(18):2574–9.
9. Bilgin H, Marku M, Yilmaz SS, Karahasan Yagci A, Sili U, Can B, et al. The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells. Vaccine. 2022;40(18):2619–25.
10. Zhang J, Dong X, Liu G, Gao Y. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin Rev Allergy Immunol. 2022;64(1):90–107.
11. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–7.
12. Raza HA, Sen P, Bhatti OA, Gupta L. Sex hormones, autoimmunity and gender disparity in COVID-19. Rheumatol Int. 2021;41(8):1375–86.
13. Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and Gender-Based Differences in COVID-19. Front Public Health. 2020;8.
14. Murray MA, Chotirmall SH. The Impact of Immunosenescence on Pulmonary Disease. Mediators Inflamm. 2015;2015:1–10.
15. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine. 2021;385(16):1474–84.
16. Shah VP, Farah WH, Hill JC, Hassett LC, Binnicker MJ, Yao JD, et al. Association Between SARS-CoV-2 Cycle Threshold Values and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Open Forum Infect Dis. 2021;8(9).